BC Industry News

Robert Lee Kilpatrick, Partner, Technology Vision Group LLC, is enthusiastic about the international participation that is evidenced in the expanding list of attendees. He comments, "This year's BPN has benefited enormously from the creation of the Global Bioscience Partnership, whose membership includes 28 bioscience associations and agencies from around the world. This partnership was created by Technology Vision Group to bring together stakeholders from emerging bioscience industries in the Asia Pacific region, Europe, North America, and the rest of the world. Looking ahead to 2005, we expect a substantially greater number of delegates to come to Vancouver from outside of Canada."

BPN is the North American version of the distinguished BioPartnering Europe conference held in London each October, which is a cornerstone of the annual conference calendar. Over 650 delegates from 373 various companies have already registered to attend BPN 2004. These numbers include 39 registered pharmaceutical companies and represent a total of 27 countries including Australia, China, Denmark, Finland, Germany, Italy, Japan and the U.K.

"Our inaugural BioPartnering North America conference last year succeeded beyond our wildest dreams in bringing British Columbian biotechnology companies to the attention of a number of delegates from around the biotech world," said Paul Stinson, Executive Director of BC Biotech. "I cannot remember how many times I heard: 'I had no idea that British Columbia had such a dynamic biotech cluster!' From our point of view, BPN 2003 was an enormous success, and we expect that BPN 2004 will be even better."

A hallmark of BPN is the Open House presentations that will feature 56 biopharmaceutical and diagnostics companies that give interactive presentations in specially constructed booths. Presenting companies are available during a 2-hour period for informal discussions with business development executives. BPN also showcases a number of young companies from various parts of the world in the Emerging Company presentations. This year, 16 companies will offer 15-minute podium presentations in the main plenary hall. Each company will then be available for private discussions directly afterwards.

Emerging Company Presenters     Ablynx, Gent, Belgium, Founded 2001     Allon Therapeutics, California, USA, Founded 2001     Ambit Biosciences, California, USA, Founded 2001     AmCyte Inc., California, USA, Founded 2001     Biota Inc., California, USA, Founded 2001     Borean Pharma A/S, Aarhus C, Denmark, Founded 2001     Crimson Pharma, New Jersey, USA, Founded 2002     GenPath Pharmaceuticals, Inc., Massachusetts, USA, Founded 2002     Ionix Pharmaceuticals, Cambridge, United Kingdom, Founded 2001     Lorantis Ltd, Cambridge, United Kingdom, Founded 2001     Nuevolution A/S, Copenhagen, Denmark, Founded 2001     PolyMedix Inc., Pennsylvania, USA, Founded 2002     RESprotect GmbH, Saxony, Germany, Founded 2001     Scion Pharmaceuticals, Massachusetts, USA, Founded 2001     Shanghai Genomics, Inc., Shanghai, China, Founded 2001     Sidec Technologies AB, Stockholm, Sweden, Founded 2001Open House Presenters     Active Pass Pharmaceuticals, British Columbia, Canada     Affymax, Inc., California, USA     AnorMED Inc., British Columbia, Canada     Antisoma Research Ltd, London, United Kingdom     Argenta Discovery Limited, Essex, United Kingdom     Astex Technology Ltd., Cambridge, UKatugen AG, Berlin, Germany     Avecia Ltd., Delaware, USA     AVI BioPharma, Inc., Oregon, USA     Avidex, Oxford, United Kingdom     Biolex, Inc., North Carolina, USA     BioVex Limited, London, United Kingdom     BioVisioN AG, Hannover, Germany     BTG, London, United Kingdom     Cardiome Pharma Corp., British Columbia, Canada     Chemokine Therapeutics Corp., British Columbia, Canada     Chromos Molecular Systems Inc., British Columbia, Canada     Coley Pharmaceutical Group, Inc., Massachusetts, USA     Corgentech, California, USA     Cyclacel Limited, Dundee, United Kingdom     Cytokinetics, Inc., California, USA     Diversa Corporation, California, USA     Epigenomics AG, Washington, USA     Evotec OAI, Oxford, United Kingdom     Favrille, Inc., California, USA     Forbes Medi-Tech Inc., British Columbia, Canada     GenWay Biotech, Inc., California, USA     Global Genomics AB, Stockholm, Sweden     Global IQ, Alberta, Canada     Graffinity Pharmaceuticals AG, Rhode Island, USA     Hybridon, Inc., Massachusetts, USA     Inex Pharmaceuticals Corporation, British Columbia, Canada     Inflazyme Pharmaceuticals, British Columbia, Canada     Ingenium Pharmaceuticals AG, Martinsried, Germany     Inimex Pharmaceuticals, Inc., British Columbia, Canada     InNexus Biotechnology Inc., British Columbia, Canada     International Wex Technologies Inc., British Columbia, Canada     Ipsat Therapies Ltd, Espoo, Finland     JERINI, Berlin, Germany     Lucigen Corporation, Wisconsin, USA     Maxim Pharmaceuticals, California, USA     MedPharm Ltd, London, United Kingdom     MorphoSys AG, Martinsried, Germany     Morphotek Inc., Pennsylvania, USA     NOBEX, North Carolina, USA     Novozymes A/S, Bagsvaerd, Denmark     Oxford BioMedica, California, USA     PanaGin Pharmaceuticals Inc., British Columbia, Canada     Plexxikon, California, USA     Scottish Biomedical, Glasgow, United Kingdom     SemBioSys Genetics Inc., Alberta, Canada     Sequenom, California, USA     Syngenta-Biopharma, Basel, Switzerland     Twinstrand Therapeutics Inc., British Columbia, Canada     Vela Pharmaceuticals Inc., New Jersey, USA     Produced by:     Technology Vision Group LLC     Hosted by:     BC Biotech, BIOTECanada, and BioAlbertaSponsored by: 

Angiotech Pharmaceuticals, Inc., Arnold & Porter, AstraZeneca, BioWa,Inc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Burrill & Company, Canadian Institutes of Health Research, Cooley Godward LLP, DDB Technology, Farris, Vaughan, Wills & Murphy Barristers & Solicitors, Genome British Columbia, Government of Alberta, Gowling Lafleur Henderson LLP, Industry Canada / Industrie Canada, Leading Edge British Columbia, Merck, PricewaterhouseCoopers LLP, QLT Inc., RBC Financial Group, Simon Fraser University, TAP Pharmaceutical Products Inc., University-Industry Liaison Office - UBC, Vancouver Economic Development Commission, Ventana Clinical Research Corporation, and Western Economic Diversification Canada.

Supported by:

Acumen Journal of Life Sciences, Biotechnology Focus, BioWorld Today, CCNMatthews, Contact Canada®, Department of International Trade, Euro RSCG Life NRP, Global Bioscience Partnership, and U.S. Commercial Service.

Global Bioscience Partnership:

Alsace Development International, APBio, AusBiotech, BayBio, BC Biotech, BIA, BioAlberta, BIOCOM, BioMelbourne Network, BioNova, BIOQuebec, BIO-SA, BIOTECanada, Biotech Consortium India Limited, CIGB, CIMAB S.A., Council of Great Lakes Governors - Australia, Council of Great Lakes Governors Canada Trade Office, DIB, EBE, ERBI, London Development Agency, Metro Atlanta Bioscience Council, Oregon Biosciences Association, and Technology Vision Group LLC.

     Technology Vision Group LLC     Nancy E. Connelly     Phone: (831) 464 7100     email: neconnelly@techvision.com     Euro RSCG Life NRP     Jeannine Medeiros     Phone: (415) 901-3709     email: jeannine.medeiros@eurorscg.com